What is the Economic Cost of Providing an All Wales Postpartum Haemorrhage Quality Improvement Initiative (OBS Cymru)? A Cost-Consequences Comparison with Standard Care.
Journal
PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
accepted:
31
07
2022
pubmed:
7
9
2022
medline:
7
9
2022
entrez:
6
9
2022
Statut:
ppublish
Résumé
A postpartum haemorrhage quality improvement initiative (the Obstetric Bleeding Strategy for Wales [OBS Cymru]), including about 60,000 maternities, was adopted across Wales (2017-2018). We performed a cost-consequences analysis to inform ongoing provision and wider uptake. Analysis was based on primary data from the All Wales postpartum haemorrhage database, with a UK National Health Services perspective, a time horizon from delivery until hospital discharge and no discounting. Costs were based on UK published sources with viscoelastic haemostatic assay costs provided by the OBS Cymru national team. Mean costs per eligible patient (postpartum haemorrhage > 1000 mL) were calculated for OBS Cymru, using the early implementation period as a comparator. Modelling allowed comparisons of three scenarios (two predefined and one post hoc) and implementation in different sizes of maternity unit. All analyses demonstrated consistent savings in blood products, critical care and haematology time, and also a reduced occurrence of massive postpartum haemorrhage (> 2500 mL). Incremental postnatal length of stay varied between scenarios, substantially impacting on total costs. Mean incremental cost of OBS Cymru, compared with standard care, across Wales was £18.41 per patient (postpartum haemorrhage > 1000 mL) or - £10.66 if the length of stay was excluded. Modelling a maternity unit of 5000 births per annum, OBS Cymru incurred an incremental cost of £9.53 per patient with postpartum haemorrhage > 1000 mL. OBS Cymru reduces the occurrence of massive postpartum haemorrhage, need for transfusions, quantity of blood products and intensive care. In medium-to-large maternity units (>3000 maternities per annum), the OBS Cymru intervention approaches cost neutrality compared to standard care.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
A postpartum haemorrhage quality improvement initiative (the Obstetric Bleeding Strategy for Wales [OBS Cymru]), including about 60,000 maternities, was adopted across Wales (2017-2018). We performed a cost-consequences analysis to inform ongoing provision and wider uptake.
METHODS
METHODS
Analysis was based on primary data from the All Wales postpartum haemorrhage database, with a UK National Health Services perspective, a time horizon from delivery until hospital discharge and no discounting. Costs were based on UK published sources with viscoelastic haemostatic assay costs provided by the OBS Cymru national team. Mean costs per eligible patient (postpartum haemorrhage > 1000 mL) were calculated for OBS Cymru, using the early implementation period as a comparator. Modelling allowed comparisons of three scenarios (two predefined and one post hoc) and implementation in different sizes of maternity unit.
RESULTS
RESULTS
All analyses demonstrated consistent savings in blood products, critical care and haematology time, and also a reduced occurrence of massive postpartum haemorrhage (> 2500 mL). Incremental postnatal length of stay varied between scenarios, substantially impacting on total costs. Mean incremental cost of OBS Cymru, compared with standard care, across Wales was £18.41 per patient (postpartum haemorrhage > 1000 mL) or - £10.66 if the length of stay was excluded. Modelling a maternity unit of 5000 births per annum, OBS Cymru incurred an incremental cost of £9.53 per patient with postpartum haemorrhage > 1000 mL.
CONCLUSIONS
CONCLUSIONS
OBS Cymru reduces the occurrence of massive postpartum haemorrhage, need for transfusions, quantity of blood products and intensive care. In medium-to-large maternity units (>3000 maternities per annum), the OBS Cymru intervention approaches cost neutrality compared to standard care.
Identifiants
pubmed: 36066836
doi: 10.1007/s41669-022-00362-2
pii: 10.1007/s41669-022-00362-2
pmc: PMC9596647
doi:
Types de publication
Journal Article
Langues
eng
Pagination
847-857Informations de copyright
© 2022. The Author(s).
Références
Br J Haematol. 2018 Sep;182(6):789-806
pubmed: 30073664
Vox Sang. 2014 Nov;107(4):381-8
pubmed: 25130704
Anaesthesia. 2015 Feb;70(2):166-75
pubmed: 25289791
BMC Pregnancy Childbirth. 2021 May 15;21(1):377
pubmed: 33992094
Health Technol Assess. 2015 Jul;19(58):1-228, v-vi
pubmed: 26215747
BJOG. 2018 Jun;125(7):874-883
pubmed: 28972301
Lancet Glob Health. 2018 Feb;6(2):e222-e228
pubmed: 29389542
Transfusion. 2018 Apr;58(4):846-853
pubmed: 29380872
Int J Obstet Anesth. 2021 Aug;47:102983
pubmed: 33994274
BMJ Open Qual. 2020 Apr;9(2):
pubmed: 32273281
J Clin Anesth. 2018 Feb;44:50-56
pubmed: 29121548
Br J Anaesth. 2017 Sep 01;119(3):411-421
pubmed: 28969312
Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:286-291
pubmed: 28088109
J Obstet Gynaecol. 2017 Jul;37(5):601-604
pubmed: 28317421
Anaesthesia. 2015 Jun;70(6):760-1
pubmed: 25959192
Int J Obstet Anesth. 2019 Feb;37:106-117
pubmed: 30322667
Pharmacoecon Open. 2019 Jun;3(2):163-176
pubmed: 30506157
Value Health. 2013 Mar-Apr;16(2):e1-5
pubmed: 23538200